Snup

Quick links to important sections

Snup

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Snup

Quick Facts

Property Description
Active Ingredient Xylometazoline Hydrochloride
Form Aqueous Nasal Solution (Spray/Drops)
Pharmacological Class Nasal Decongestant (Alpha-adrenergic agonist)
Common Purpose Relief from nasal blockage and congestion
Origin Synthetic Compound (Imidazoline derivative)

Definition, Active Ingredient, and Drug Class

Snup is a brand of medicine that utilizes the active substance Xylometazoline Hydrochloride. This preparation is chemically classified as an imidazoline derivative and is a synthetic compound, meaning it is manufactured chemically rather than derived from natural sources. Xylometazoline is categorized as a Nasal Decongestant and functions pharmacologically as a sympathomimetic agent. This drug class works by stimulating certain receptors in the body that cause the narrowing of blood vessels.

As a widely recognized decongestant, Snup is distinguished by its typical availability as an Over-The-Counter (OTC) medicine, making it accessible for temporary symptom relief. The brand is often formulated with specific concentrations tailored for adults and children, accounting for differential safety profiles across patient groups.


Form, Delivery, and General Purpose

Snup is formulated as an aqueous nasal solution intended for intranasal administration, typically supplied as a metered-dose spray or as drops. This specific delivery system ensures the active ingredient is applied directly to the lining of the nose, facilitating a fast-acting and localized effect. The primary vehicle of the solution is water, enhancing dispersal and local tolerability.

The general purpose of this medicine is to provide rapid and reliable relief from nasal blockage and congestion. This action is intended for treating the symptoms associated with a common cold or seasonal allergies. Xylometazoline achieves this by causing the blood vessels in the nasal lining to narrow (vasoconstriction), which in turn reduces the fluid and swelling of the congested tissues. This mechanism is associated with a decrease in nasal airway resistance, thereby temporarily restoring clearer breathing.

Regulatory References

  1. Xylometazoline Nasal Spray: DailyMed - NIH

What side effects are possible with Snup?

Possible Side Effects and Safety Information

The safety profile of Xylometazoline Hydrochloride, the active ingredient in Snup, is officially documented by regulatory authorities and is classified based on the frequency and the affected system-organ class. The most frequently reported adverse reactions are generally localized to the site of administration.

Officially Documented Adverse Reactions

Frequency Classification Affected Systems and Examples
Common Nasal dryness, nasal discomfort, burning sensation at the application site, headache, nausea.
Uncommon Epistaxis (nosebleed).
Very Rare Hypersensitivity reactions (e.g., angioedema), transient visual impairment, increased heart rate (tachycardia), irregular heart rhythm (arrhythmias), and apnoea (cessation of breathing) in young infants.

Key Safety Patterns and Constraints

A critical safety pattern documented in regulatory texts is the risk of rebound congestion, also known as rhinitis medicamentosa, which is associated with prolonged or excessive use of the medicine. This condition involves the nasal obstruction worsening after the decongestant effect wears off.

Specific safety constraints are outlined for individuals with certain pre-existing conditions due to the drug’s sympathomimetic classification. The medicine is contraindicated in patients with narrow-angle glaucoma and rhinitis sicca (chronic nasal dryness). Furthermore, caution is required in patients with conditions such as hypertension, cardiovascular disease, hyperthyroidism, and diabetes mellitus. Use alongside certain medications, like Monoamine Oxidase Inhibitors (MAOIs), is restricted due to the potential for severe cardiovascular consequences.

Overdose and Emergency Response

The official regulatory profile for Xylometazoline overdose documents a range of severe clinical manifestations affecting the cardiovascular and central nervous systems. Documented presentations include both initial CNS stimulation (e.g., agitation, hallucinations, severe dizziness) and subsequent depression, potentially leading to convulsions, respiratory depression, and coma. Cardiovascular effects noted are serious, such as hypertension that may be followed by a shock-like drop in blood pressure, as well as cardiac arrhythmia and the risk of cardiac arrest. The symptoms of pallor, cyanosis, and profuse perspiration are also documented.

Immediate medical help must be sought if the product is accidentally swallowed or if the affected individual displays serious signs like trouble breathing or passing out. Regulatory instructions mandate contacting a Poison Control Center or emergency services in these events. Severe cases require intensive inpatient treatment.

The management approach, as described in regulatory documents, centers on urgent symptomatic and supportive treatment under medical supervision, since no specific antidote is known. This may include decontamination procedures and the use of targeted agents, such as phentolamine to reduce high blood pressure. The official labeling highlights that small children and infants are more sensitive to systemic toxicity, with cases of apnoea and severe CNS depression documented in this population, requiring careful observation for several hours.

Therapeutic Uses of Snup

Main Uses and Benefits of Snup

Snup is a nasal spray containing xylometazoline hydrochloride, a medication used to relieve symptoms associated with nasal congestion. It is primarily utilized to facilitate easier breathing when the nasal passages become blocked due to various conditions.

Therapeutic Indications

Snup is indicated for the following uses:

  • Reduction of Nasal Swelling: The primary function of the active ingredient is to constrict the blood vessels in the nasal mucosa. This action reduces swelling and inflammation, which helps to clear the nasal passages.
  • Treatment of Rhinitis: It is used for the short-term treatment of nasal congestion associated with the common cold or acute rhinitis.
  • Allergic Rhinitis: The spray can provide temporary relief from the nasal stuffiness caused by hay fever or other allergic reactions affecting the upper respiratory tract.
  • Sinusitis Relief: By promoting the drainage of secretions, it may be used as supportive treatment to alleviate pressure and congestion in the sinuses.
  • Facilitation of Medical Procedures: In some clinical settings, it may be used to reduce swelling of the mucous membranes to assist in diagnostic examinations of the nasal passages.

Benefits for the Patient

The use of Snup provides several practical benefits for individuals experiencing upper respiratory discomfort:

  • Rapid Onset of Action: The medication typically begins to work within a few minutes of application, providing quick relief from the sensation of a blocked nose.
  • Improved Airflow: By reducing the volume of the swollen tissue, the spray increases the space within the nostrils, allowing for more efficient inhalation and exhalation.
  • Support for Recovery: Clearing nasal passages can improve overall comfort and may help facilitate better sleep and rest during a viral or allergic illness.
  • Ease of Secretion Removal: Reduced swelling allows for easier clearance of mucus, which prevents the buildup of pressure within the nasal cavity and associated areas.

Regulatory References

  1. DailyMed official drug label information

Eligibility and Restrictions for Use

The use of Snup is governed by official regulatory criteria that specify the populations who must avoid the medicine due to established risks or lack of confirmed safety data.

Formal Contraindications (Do Not Use)

Snup is formally contraindicated in patients with a known hypersensitivity or allergy to the active substance (xylometazoline) or any of the product's excipients. It must also not be used during pregnancy or breastfeeding, nor in patients receiving treatment with monoamine oxidase inhibitors (MAO inhibitors) or other medications that could potentially increase blood pressure, due to the risk of serious adverse effects.

Restricted Use and Special Considerations

The medicine is not for use in children under 6 years of age, as safety and efficacy have not been established in the pediatric population. Use requires special medical advice and monitoring for individuals diagnosed with certain pre-existing conditions, including severe cardiovascular disease, high blood pressure (hypertension), narrow-angle glaucoma (increased eye pressure), an overactive thyroid (hyperthyroidism), prostatic enlargement, or diabetes mellitus. Use is limited to a maximum of 7 consecutive days to prevent the risk of rebound congestion.

What should I know about interactions with other medicines?

The interaction profile for Xylometazoline Hydrochloride (the active substance in Snup) is primarily defined by its sympathomimetic action, which restricts its use with certain other medicines that also affect the cardiovascular system.

Contraindicated Combinations and Mandatory Timing Rules

The most critical interaction restriction is the formal contraindication with Monoamine Oxidase Inhibitors (MAOIs). Co-administration of Xylometazoline with MAOIs is strictly prohibited due to the potential for a severe increase in blood pressure, known as a hypertensive crisis. This restriction extends beyond the co-administration period; the medicine must not be used if the patient has ceased MAOI therapy within the previous 14 days.


Pharmacodynamic Potentiation

Interactions classified as pharmacodynamic potentiation are documented with certain antidepressant classes. The co-administration of Xylometazoline with tricyclic and tetracyclic antidepressants is associated with an increased risk of elevated blood pressure. This effect stems from the additive cardiovascular stimulation caused by both substances.


Population-Specific Caution

A specific population caution noted in regulatory documentation involves individuals with Long QT syndrome. For this group, treatment with Xylometazoline carries a documented increased risk of developing serious ventricular arrhythmias. No specific interactions with food, alcohol, or herbal products are formally documented in official regulatory labeling.

Mechanism of Action

Binding to the A3 Receptor

Snup functions by specifically binding to the A 3 receptor located on the surface of mature osteoclasts. This binding event initiates an intracellular signaling cascade that involves the p38 mitogen-activated protein kinase ( MAPK) pathway.


Inhibition of Osteoclast Gene Expression

The activation of p38 MAPK results in the phosphorylation and subsequent ubiquitination of the NFATc1 transcription factor. NFATc1 is thereby prevented from translocating to the nucleus, which downregulates the expression of essential genes required for osteoclast function and survival, including cathepsin K. This sequence leads to the rapid inhibition of the resorptive activity of the osteoclast and subsequently induces osteoclast apoptosis.


Physiological Effect on Bone Remodeling

The reduction in bone resorption activity shifts the balance toward net bone formation over time. The mechanistic effect increases the bone mineral density ( BMD) measurement.

Dosage and Administration Information

How to Use Snup: Administration Guidelines

Snup (Xylometazoline Hydrochloride) is a medicine intended for intranasal use and is administered as an aqueous nasal solution (either spray or drops). The product is used to follow a standardized, time-limited course, with administration patterns defined by specific dosage schedules.


Dosage and Frequency Principles

Administration Scope Detail
Standard Adult Dose (0.1% strength) 1 to 3 applications (sprays or drops) in each nostril.
Maximum Frequency Up to 3 times daily, with an interval of at least 8 to 10 hours between doses.
Age-Group Rule The 0.1% concentration is generally not recommended for children under 12 years of age.

Procedural and Duration Constraints

The correct use of this medicine depends on adhering to specific instructions regarding the course length and administration technique. Guidelines indicate that Snup must not be used for more than 3 to 7 consecutive days, as prolonged use can lead to the recurrence or worsening of nasal congestion (rebound effect). An interval of several days should elapse before re-administering the product if long-term use is attempted.

For nasal spray forms, the metered pump requires priming—actuating it until an even mist is produced—before the first use. To prevent the spread of infection, the product container should not be shared among multiple individuals. Doses should not be exceeded, and the medicine is used on an as-needed basis when congestion occurs, while respecting the maximum daily frequency.

Standard protocols establish a precise framework that centers on the intranasal route and a strict time limit for use, defining the standardized maximum dose, frequency, and duration allowed.

Recent Clinical Evidence

Research evidence / Overview of Studies for Snup

This section outlines the types of studies that have examined the clinical effects of Xylometazoline, focusing on how research is structured and what remains unknown, without offering advice or clinical interpretation.


Evidence for Use in Nasal Congestion from the Common Cold

Much of the research for Xylometazoline has been studied in the context of the common cold (acute rhinitis), primarily through short-term Randomized Controlled Trials (RCTs). These trials compared the medicine against an inactive solution (a placebo) in adult and adolescent populations. Researchers monitored objective outcomes, such as measuring nasal airflow, and patient-reported outcomes describing perceived discomfort. Findings describe patterns where an initial rapid change in nasal airflow measurements was reported shortly after administration. Studies monitored the duration of the decongestive response, which was observed to last for several hours following a single dose.

Evidence for Use in Allergic Rhinitis and Sinusitis

Research has also explored the use of Xylometazoline in individuals experiencing nasal congestion associated with allergic rhinitis (hay fever) and acute rhinosinusitis. In these contexts, studies often evaluated the medicine as supportive care alongside other primary treatments. For acute rhinosinusitis, research examined outcomes such as changes in facial pain/pressure scores and objective measurements of mucosal swelling monitored through rhinoscopy. Research is ongoing to determine the isolated role of Xylometazoline when used as a component of a multi-drug regimen for complex conditions like rhinosinusitis.

Research Gaps and Areas of Uncertainty

Follow-up durations were limited in most efficacy studies, meaning long-term effects are not fully established. Studies exploring prolonged use show patterns associated with rebound congestion (a return or worsening of nasal blockage) when usage exceeds the defined time limit studied in the trials. Data for certain pediatric groups remain insufficient, and the research available resulted in specific use restrictions. The evidence quality for the elderly and individuals with certain pre-existing conditions (like cardiovascular disease) varies across studies, highlighting areas for more research and specific regulatory attention.

Key Studies & References

  1. The efficacy of xylometazoline, the risk of rhinitis medicamentosa (RM), and treatment strategies: A review of published studies
  2. Sinusitis (acute): antimicrobial prescribing - NICE Guideline NG79
  3. DailyMed Label: SINOSIL NASAL DECONGESTANT - xylometazoline hcl spray (Regulatory Document)
  4. Public Assessment Report (PAR) Xylomare 0.5 mg/ml and 1 mg/ml, nasal spray, solution (Regulatory Document)
  5. Rhinosinusitis treatment protocol (Clinical Guidance, Ministry of Health, Saudi Arabia)

Frequently Asked Questions (FAQ)

Common questions about Snup (FAQ)


Q: What is the main reason Snup is prescribed?

A: According to official regulatory documents, Snup is intended for the temporary relief of nasal congestion. This congestion may be caused by common conditions like the cold, hay fever, or other respiratory allergies.

Q: Is Snup used to treat anything else besides the main condition?

A: Official product information specifies the drug's approved purpose is the relief of nasal congestion linked to conditions like colds, hay fever, or allergic rhinitis. The regulatory documents do not list any other indications for use.

Q: Is Snup the same type of medicine as [Similar Drug]?

A: Snup is officially classified as a nasal decongestant. This means it belongs to a class of medicines that act as an alpha-adrenergic agonist, which is how it helps reduce swelling in the nasal passages.

Q: What are the most common side effects of Snup that people report?

A: The most commonly reported side effects are localized reactions at the site of application. These typically include burning, stinging, or dryness inside the nose, as well as temporary sneezing or an increase in nasal discharge.

Q: Is Snup known to affect sleep?

A: Official information indicates that, in some instances, the product is associated with trouble sleeping (insomnia) or nervousness. These are recognized potential reactions stemming from its classification as a sympathomimetic agent.

Q: Are there any long-term side effects associated with Snup use?

A: Official warnings describe constraints against prolonged or excessive use because regulatory documents cite a potential for a specific long-term effect. This condition, known as rhinitis medicamentosa, is a rebound effect where the nasal congestion may return or worsen.

Q: If I experience a mild side effect from Snup, is that normal?

A: Regulatory labeling lists temporary local discomforts, such as burning, stinging, or nasal dryness, as possible side effects. These effects are listed as potential side effects in the product’s official information.

Q: How quickly does Snup start to work?

A: According to official product information, the decongestant effect typically begins within a few minutes after the product has been applied.

Q: How long after starting Snup should I expect to feel a difference?

A: The effects of the medicine are generally rapid, and a difference in nasal congestion is usually observed within a few minutes of application.

Q: Is Snup something I will need to take forever?

A: No. Regulatory labeling advises against use for more than 3 to 7 consecutive days. This constraint is in place due to the potential risk of developing rhinitis medicamentosa, commonly referred to as the rebound effect.

Q: Does stopping Snup suddenly cause any specific issues?

A: The main issue noted in official warnings is the rebound effect, which occurs when the product is stopped after a period of prolonged use. This effect causes the nasal congestion to return or worsen.

Q: Can Snup be used by older adults?

A: The medicine is intended for use by adults, and dosage guidance for the elderly is typically the same as for other adults. However, official documents note that caution may be appropriate for older patients who have pre-existing conditions like hypertension (high blood pressure) or heart disease.

Q: What are the general rules for who cannot use Snup?

A: Official documents state that certain conditions are contraindications (reasons not to use the product). These include having narrow-angle glaucoma or rhinitis sicca, having undergone specific surgeries (such as trans-sphenoidal hypophysectomy), or concurrent use of Monoamine Oxidase (MAO) inhibitors.

Q: Is Snup safe to take during pregnancy or while breastfeeding?

A: For individuals who are pregnant or breastfeeding, regulatory labeling describes the importance of discussing use with a physician before using the product. This is to ensure the appropriate medical considerations are taken for individual circumstances.

Q: Is Snup a controlled substance or habit-forming?

A: Snup is not classified as a controlled substance. However, regulatory information warns that prolonged use is associated with rebound congestion, a condition where the nasal passages develop a physical dependency on the medicine for relief.

Q: What if Snup doesn't seem to be working for me after a few weeks?

A: Because the product is subject to a maximum use period of 3 to 7 days, official guidance states that continued use beyond this duration or symptoms persisting or worsening requires consultation with a physician.

Q: What happens in the body when Snup is taken?

A: The medicine works by stimulating adrenergic receptors in the nasal lining. This action causes the blood vessels in the nose to constrict (narrow), which rapidly reduces the swelling of the nasal tissues to relieve congestion.

Q: Is it possible to become resistant to Snup over time?

A: The regulatory information warns that frequent or prolonged use can cause congestion to recur or worsen. This phenomenon is sometimes described by users as a decrease in effectiveness or tolerance over time.

Q: Can Snup make me feel tired or drowsy?

A: Official product information states that the medicine has no or negligible influence on the ability to drive or operate machinery. This suggests the risk of experiencing general tiredness or drowsiness is low.

Q: Are allergic reactions to Snup common?

A: Severe allergic reactions are possible and are listed in official information. However, systemic reactions are generally described as uncommon. Local side effects, such as stinging or dryness in the nose, are reported more frequently.

Q: What are the signs of a serious side effect from Snup?

A: Symptoms that regulatory sources list as serious and that should prompt medical attention include fast or pounding heartbeats, blurred vision, dizziness, or a light-headed feeling.

Q: Does Snup affect blood pressure or heart rate?

A: Official warnings describe the importance of discussing use with a healthcare provider for patients with heart disease or high blood pressure. This is because the medicine is associated with the potential for a temporary increase in blood pressure or fast or pounding heartbeats.

Q: Can I take Snup if I have a history of liver problems?

A: Official guidance describes the importance of discussing use with a healthcare provider for patients with certain pre-existing conditions, including liver disease. This helps ensure the medicine's appropriateness is medically considered.

Q: Do I need to change my activities while taking Snup?

A: Official documentation states that the medicine has no or negligible influence on the ability to drive or operate machinery.

Q: What does the official drug label say about Snup's purpose?

A: The official drug label describes the product's purpose as providing temporary relief of nasal congestion. This includes congestion related to the common cold, hay fever, and respiratory allergies.

Q: Is Snup a drug that requires regular blood tests?

A: Regulatory administration guidelines and warnings for Snup do not specify that regular blood tests are required when using this product.

Q: Can Snup cause problems with driving or operating machinery?

A: Official product information states that the medicine has no or negligible influence on the ability to drive or operate machinery.

Q: How common are changes in mood or thinking while taking Snup?

A: Changes in mood or thinking are listed as a potential side effect in official documents. However, local nasal effects such as stinging or dryness are reported as more common.

Q: What is the maximum amount of time Snup has been studied for continuous use?

A: Regulatory documents specify a maximum recommended use duration of 3 to 7 consecutive days to prevent safety issues like the rebound effect. This duration is deemed appropriate by regulatory bodies for over-the-counter use.

Q: If I have kidney issues, is Snup still an option?

A: Official guidance describes the importance of discussing use with a healthcare provider for patients with certain pre-existing conditions, including kidney disease. This allows for the appropriate medical determination of the product’s suitability.

Q: Is Snup described as a 'cure' for the condition it treats?

A: No. Official documents consistently describe the medicine as providing temporary relief of symptoms, such as nasal congestion. It is not described as a cure for the underlying condition causing the congestion.

Q: Does Snup interact with common cold or flu medicines?

A: Official interaction warnings are focused on specific classes of medicines. These include Monoamine Oxidase Inhibitors (MAOIs) and tri- and tetra-cyclic antidepressants, as using Snup with these may increase the risk of elevated blood pressure.

Q: If Snup makes me feel restless, is that a side effect?

A: Official warnings caution that the medicine is part of a class of substances that can cause signs of nervousness, tremor, or insomnia. These effects may be perceived by a user as restlessness.

Q: Does Snup have any known effects on mental clarity?

A: Mental or mood changes are listed as a potential side effect in official documents. However, the product information states that the overall influence on the ability to drive or operate machinery is negligible.

How should Snup be stored and disposed of?

Storage and Disposal Requirements for Snup (Xylometazoline Hydrochloride)

Official Storage Conditions

Snup nasal solution must be stored at a temperature below 30 C to maintain product stability, as documented in official regulatory labeling. For safety, the medicine must be kept out of the sight and reach of children at all times.

Stability and Disposal

The product's stability is time-limited once opened. The nasal spray solution should not be used for longer than 12 months after the initial opening.

Disposal of unused or expired Snup should follow official guidelines, prioritizing a drug take-back program. If this option is unavailable, the product may be discarded in household trash after being mixed with an undesirable substance, following the specific procedures outlined by national health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Snup found in:

A-Z Index: